No Data
No Data
Mizuho Securities Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating
Scotiabank Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $18
Express News | Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $33 Price Target
EyePoint Pharmaceuticals Analyst Ratings
A Quick Look at Today's Ratings for EyePoint Pharmaceuticals(EYPT.US), With a Forecast Between $18 to $45
EyePoint Pharmaceuticals Stock Gains 3% After Positive Phase 2 Trial Results
kingrotch : thank you for your work![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f-1f3fb.png)
![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f-1f3fb.png)
![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f-1f3fb.png)
真名有晨 : Thank you very much
Please take care and rest.
iluvpoptarts : sry doc. I'm too busy counting the money your making me too look. muha
IamBadNewz : @Jaguar8 Been waiting (im)patiently for a pop on CGTX given the recent conference and news of insider buying but price hasn’t reacted. Your thoughts?
Jaguar8 OP IamBadNewz : You have to be patient
View more comments...